JP2024512741A - 腫瘍及び/又は免疫細胞を標的化する結合剤 - Google Patents
腫瘍及び/又は免疫細胞を標的化する結合剤 Download PDFInfo
- Publication number
- JP2024512741A JP2024512741A JP2023560694A JP2023560694A JP2024512741A JP 2024512741 A JP2024512741 A JP 2024512741A JP 2023560694 A JP2023560694 A JP 2023560694A JP 2023560694 A JP2023560694 A JP 2023560694A JP 2024512741 A JP2024512741 A JP 2024512741A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antigen
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168606P | 2021-03-31 | 2021-03-31 | |
| US63/168,606 | 2021-03-31 | ||
| US202163249784P | 2021-09-29 | 2021-09-29 | |
| US63/249,784 | 2021-09-29 | ||
| US202263301305P | 2022-01-20 | 2022-01-20 | |
| US63/301,305 | 2022-01-20 | ||
| PCT/CA2022/050442 WO2022204793A1 (en) | 2021-03-31 | 2022-03-25 | Binding agents targeting tumors and/or immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512741A true JP2024512741A (ja) | 2024-03-19 |
| JP2024512741A5 JP2024512741A5 (cg-RX-API-DMAC7.html) | 2025-04-03 |
Family
ID=83455216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560694A Pending JP2024512741A (ja) | 2021-03-31 | 2022-03-25 | 腫瘍及び/又は免疫細胞を標的化する結合剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240166739A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314076A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024512741A (cg-RX-API-DMAC7.html) |
| AR (1) | AR125264A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174330A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304993A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022204793A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4599066A1 (en) * | 2022-10-03 | 2025-08-13 | Kisoji Biotechnology Inc. | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof |
| CN120265659A (zh) * | 2022-10-25 | 2025-07-04 | 加拿大商木曾路生物科技公司 | 靶向表达cd36的肿瘤细胞的结合剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012512646A (ja) * | 2008-12-19 | 2012-06-07 | アブリンクス エン.ヴェー. | 免疫グロブリン配列を生成する方法 |
| JP2020523559A (ja) * | 2017-05-24 | 2020-08-06 | ナノソミックス・インコーポレイテッドNanoSomiX, Inc. | 疾病および障害の診断および予後判定のための小胞上のバイオマーカーの検出 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009508521A (ja) * | 2005-09-23 | 2009-03-05 | アカデミッシュ ジーケンハイス レイデン | タンパク凝集に関連する疾患の診断予防及び治療のためのvhh |
| WO2011051327A2 (en) * | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| US20180222966A1 (en) * | 2013-04-29 | 2018-08-09 | Agrosavfe N.V. | Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody |
| US10874685B2 (en) * | 2014-04-17 | 2020-12-29 | The Royal Institution For The Advancement Of Learning/Mcgill University | Pancreatic cancer therapy and diagnosis |
| CA2975655C (en) * | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| WO2019179434A1 (en) * | 2018-03-20 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/cd47 antibody molecules |
| CN114072426B (zh) * | 2019-07-08 | 2024-01-26 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
-
2022
- 2022-03-25 EP EP22778240.6A patent/EP4314076A4/en active Pending
- 2022-03-25 WO PCT/CA2022/050442 patent/WO2022204793A1/en not_active Ceased
- 2022-03-25 US US18/283,579 patent/US20240166739A1/en active Pending
- 2022-03-25 JP JP2023560694A patent/JP2024512741A/ja active Pending
- 2022-03-25 CA CA3174330A patent/CA3174330A1/en active Pending
- 2022-03-31 AR ARP220100796A patent/AR125264A1/es unknown
- 2022-03-31 TW TW111112543A patent/TW202304993A/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012512646A (ja) * | 2008-12-19 | 2012-06-07 | アブリンクス エン.ヴェー. | 免疫グロブリン配列を生成する方法 |
| JP2020523559A (ja) * | 2017-05-24 | 2020-08-06 | ナノソミックス・インコーポレイテッドNanoSomiX, Inc. | 疾病および障害の診断および予後判定のための小胞上のバイオマーカーの検出 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240166739A1 (en) | 2024-05-23 |
| CA3174330A1 (en) | 2022-09-30 |
| EP4314076A1 (en) | 2024-02-07 |
| AR125264A1 (es) | 2023-06-28 |
| WO2022204793A1 (en) | 2022-10-06 |
| TW202304993A (zh) | 2023-02-01 |
| EP4314076A4 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI830761B (zh) | 針對cldn18.2和cd3之抗體構建體 | |
| TWI907375B (zh) | 多肽、蛋白質複合物及其製造方法 | |
| EP3204415B1 (en) | Bispecific antibodies against cd3epsilon and ror1 | |
| US10253104B2 (en) | Bispecific antibodies against CD3ϵ and BCMA | |
| JP7858665B2 (ja) | Ror1およびcd3に対する特異性を有する多重特異性抗体 | |
| JP2022551081A (ja) | 癌処置のための多重特異性結合タンパク質 | |
| US20240166739A1 (en) | Binding agents targeting tumors and/or immune cells | |
| KR20250143344A (ko) | 항-cdh6 항체 및 이의 용도 | |
| CN119698294A (zh) | 结合γ-δT细胞受体的变体抗体 | |
| CN117157322A (zh) | 靶向肿瘤和/或免疫细胞的结合剂 | |
| US20250313638A1 (en) | Multispecific binding agents targeting dopamine receptor d2 and methods of use thereof | |
| US20250326857A1 (en) | Binding agents targeting cd36-expressing tumor cells | |
| KR20250158060A (ko) | 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법 | |
| KR20250156803A (ko) | 항-cd3 다중특이적 항체 및 사용 방법 | |
| JP2025525291A (ja) | ガンマ-デルタt細胞受容体に結合する抗体を含む組成物 | |
| WO2024184810A1 (en) | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use | |
| HK1218299B (en) | Bispecific antibodies against cd3epsilon and bcma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260423 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260714 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20260730 |